Susan Coats, APRN
Family · Oklahoma City, OKNPI 1316437825
Payments from drug & device makers
Across 282 payments — averaging $22.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Livanova USA, Inc.$647
- UCB, Inc.$537
- Teva Pharmaceuticals USA, Inc.$374
- Neurocrine Biosciences, Inc.$335
- Pfizer$291
- plus $3K from 33 others
What the payments were for
- Travel & lodging$62510%
- Food & beverage$5,60590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 85 | $1,357 |
| Livanova USA, Inc. | 2 | $647 |
| UCB, Inc. | 27 | $537 |
| Teva Pharmaceuticals USA, Inc. | 17 | $374 |
| Neurocrine Biosciences, Inc. | 20 | $335 |
| Pfizer | 19 | $291 |
| Eisai Inc. | 11 | $288 |
| Lundbeck LLC | 7 | $265 |
| GE HealthCare | 8 | $176 |
| Amgen | 9 | $173 |
| SK Life Science, Inc. | 7 | $156 |
| Axsome Therapeutics, Inc. | 2 | $143 |
| Genentech USA, Inc. | 6 | $124 |
| Novartis | 7 | $121 |
| Merz Pharmaceuticals, LLC | 4 | $112 |
| AstraZeneca | 4 | $93 |
| Octapharma USA, Inc. | 1 | $90 |
| Amneal Pharmaceuticals LLC | 4 | $87 |
| TG Therapeutics, Inc. | 3 | $85 |
| Argenx US, Inc. | 4 | $81 |
| Alnylam Pharmaceuticals Inc. | 3 | $72 |
| Lilly USA, LLC | 4 | $71 |
| Acadia Pharmaceuticals Inc | 4 | $70 |
| Jazz Pharmaceuticals Inc. | 2 | $65 |
| Averitas Pharma Inc. | 3 | $53 |
| Catalyst Pharmaceuticals, Inc. | 2 | $50 |
| Biogen | 2 | $42 |
| Supernus Pharmaceuticals, Inc. | 2 | $35 |
| Bristol Myers Squibb | 2 | $34 |
| Ipsen Biopharmaceuticals, Inc | 1 | $34 |
| Impel Pharmaceuticals Inc. | 2 | $30 |
| Sanofi | 1 | $23 |
| NS Pharma, Inc. | 1 | $20 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Neurelis, Inc. | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $16 |
| GSK | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$625
- QULIPTA$125
- UBRELVY$125
- Symbravo$117
- VYEPTI$107
How this compares
$6,229 in reported general payments places this provider in the 95th percentile of 2,026 family providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Emgality SyringeGalcanezumab-Gnlm | 13 | $21,816 |
| Emgality PenGalcanezumab-Gnlm | 31 | $21,384 |
| Glatiramer Acetate | 12 | $14,835 |
| Aimovig AutoinjectorErenumab-Aooe | 20 | $14,230 |
| Nurtec OdtRimegepant Sulfate | 12 | $12,754 |
| Memantine Hcl | 236 | $8,376 |
| NamzaricMemantine Hcl/Donepezil Hcl | 12 | $6,843 |
| Donepezil Hcl | 231 | $2,881 |
| Levetiracetam | 97 | $2,543 |
| Gabapentin | 94 | $1,544 |
| Sumatriptan Succinate | 55 | $1,439 |
| Duloxetine Hcl | 55 | $1,155 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 34 | $1,108 |
| Pregabalin | 69 | $970 |
| Carbamazepine | 14 | $765 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $291 | $12,75412 claims |
| AbbVieNamzaric | $1,357 | $6,84312 claims |
| Lilly USA, LLCOlanzapine | $71 | $24811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,026 family providers in Oklahoma.
Other family in Oklahoma City
- April WilcoxOklahoma City$245K
- Jeremy MorganOklahoma City$63K
- Samantha BellingerOklahoma City$39K
- Lacey HillOklahoma City$20K
- Julia John SamuelOklahoma City$17K
- Kristina SnyderOklahoma City$15K
- Lindi CiglarOklahoma City$15K
- Shymol JohnOklahoma City$14K
- Xiomara PorrasOklahoma City$12K
- Anne DudeOklahoma City$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.